Schedule 13G ownership disclosure

ACRIVON THERAPEUTICS INC

Common Stock, par value $0.001 per share · CUSIP: 004890109

Event date: 2025-03-31

Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.

Filing-level shares
Unavailable
Percent of class
Unavailable
  • Citadel Advisors LLC

    Shares: 1,895,519.00 · Class: 6.0%

  • Citadel Advisors Holdings LP

    Shares: 1,895,519.00 · Class: 6.0%

  • Citadel GP LLC

    Shares: 1,895,519.00 · Class: 6.0%

  • Citadel Securities LLC

    Shares: 99.00 · Class: 0.0%

  • Citadel Securities Group LP

    Shares: 99.00 · Class: 0.0%

  • Citadel Securities GP LLC

    Shares: 99.00 · Class: 0.0%

  • Kenneth Griffin

    Shares: 1,895,618.00 · Class: 6.0%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0001104659-25-049618
Form type
SCHEDULE 13G/A
Filer
Acrivon Therapeutics, Inc.
CIK
CIK 1781174
Filed
May 15, 2025
Reporting period
Mar 31, 2025
Description
Schedule 13G beneficial ownership

Explore SEC Filings Hub